The digital transformation of the cardiology field in the coming years will have a huge impact on the delivery of healthcare, said John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology.
The digital transformation of the cardiology field in the coming years will have a huge impact on the delivery of healthcare, said John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology.
Transcript (slightly modified)
In what ways have technology advancements already improved cardiovascular medicine and patient outcomes?
Well, that’s a very big question because the world of cardiology is one that is actually very technology focused. Over many years we’ve seen amazing advancements and pacemakers and defibrillators and interventional cardiology, and now, transcatheter valves. Technology even informs on how pharmaceuticals have advanced, as well. In parallel, we’ve seen some advancements in the technical world of how hospitals are run—certainly in monitoring patients in coronary care units, for example. We even have some things that have reached out beyond the hospital walls—things starting to creep like telemedicine, pre-hospital EKGs, and so forth. But, when you ask that question, what really jumps to mind for me is not how has the core of medical technology influenced cardiology, I think most people know cardiology is a very technology intensive field, but the real question is: what lies at the future for the digital transformation of healthcare?
I think the question on everybody’s mind around technology and innovation right now is: what are we going to do with digital health, with analytics such as artificial intelligence and machine learning, and precision medicine? How are we going to change the way we deliver care, so-called care delivery innovation, where we move from a primary focus on hospitals and clinics to also including care for patients at home where they live, where they may be monitored by wearable sensors, etc? So, when you ask how has technology already changed cardiology, it’s fundamentally changed it over the last 50 or 100 years—it’s a high-tech field. But, I think what’s really exciting is to look forward at the next 5, 10, and 20 years, and expect or hope for the digital transformation of healthcare delivery.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More